Titre Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men Type de publication Article de revue Auteur Kaufman, J-M [1], Audran, Maurice [2], Bianchi, G [3], Braga, V [4], Diaz-Curiel, M [5], Francis, R.M. [6], Goemaere, S [7], Josse, R [8], Palacios, S [9], Ringe, J.D. [10], Felsenberg, D [11], Boonen, Steven [12] Editeur scientifique Endocrine Society, [13] Résumé en anglais CONTEXT: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis. OBJECTIVE: The objective of this study was to determine the efficacy and safety of strontium ranelate in osteoporosis in men over 2 years (main analysis after 1 year). DESIGN: This was an international, unbalanced (2:1), double-blind, randomized placebo-controlled trial (MALEO [MALE Osteoporosis]). SETTING: This international study included 54 centers in 14 countries. PARTICIPANTS: PARTICIPANTS were 261 white men with primary osteoporosis. INTERVENTION: Strontium ranelate at 2 g/d (n = 174) or placebo (n = 87) was administered. MAIN OUTCOME MEASURES: Lumbar spine (L2-L4), femoral neck, and total hip bone mineral density (BMD), biochemical bone markers, and safety were measured.
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